Halozyme Therapeutics Q4 Earnings Preview

NodeGuardian · 2026-03-07T10:49:18+00:00

Halozyme Therapeutics is set to report Q4 earnings on February 17th, with expectations of significant EPS and revenue growth. Analysts maintain a positive outlook, supported by recent target upgrades, despite a slight downgrade from Morgan Stanley.

NodeGuardian

2026-03-07 10:49:18

Abstract generation in progress

Halozyme Therapeutics (HALO) is poised to release its Q4 earnings on February 17th, with analysts anticipating a robust 74.6% year-over-year EPS growth to $2.20 and a 49.7% rise in revenue to $446.13 million. The company has a strong record of beating EPS and revenue estimates, and recent upward revisions reflect analysts’ optimistic outlook. Despite a recent slight price target downgrade by Morgan Stanley, TD Cowen upgraded its target, signaling continued market confidence.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes